Technical Data
SARM1, CT (Sterile alpha and TIR Motif-containing Protein 1, Sterile alpha and Armadillo Repeat Protein, Sterile alpha Motif Domain-containing Protein 2, SAM Domain-containing Protein 2, Tir-1 Homolog, KIAA0524, SAMD2, SARM)
Toll-like receptors (TLRs) are signaling molecules that recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses. SARM (SAM and ARM-containing protein), along with other molecules such as TIRP, TRIF, TIRAP, and MyD88, is thought to serve as an adaptor protein for the TLRs that allows for the activation of downstream kinases and NF-kB, and ultimately the expression of proteins involved in host defense. While SARM has not been conclusively shown to associate directly with TLRs, the presence of a Toll-interluekin-1 (TIR) domain in SARM is consistent with a role as a signaling molecule. IN zebrafish model, RNAi suppression of zebrafish peptidoglycan recognition protein 6 (zfPGRP6) mediated differentially expressed genes involved in Toll-like receptor signaling pathway and caused increased susceptibility to Flavobacterium columnare.

Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 1:5000-1:20,000
Western Blot: 1:500-1:1000
Optimal dilutions to be determined by the researcher.

Control Peptide: S0097-70P

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
250ul-20CBlue IceZebrafishRabbit
Not determined
Synthetic peptide corresponding to the C-terminal region of zebrafish SARM1.
Purified by immunoaffinity chromatography.
Supplied as a liquid in 40mM MOPS, pH 7.5, 0.1% BSA, 0.05% sodium azide, 50% glycerol.
Recognizes zebrafish SARM1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Vogel, SN. et al. Mol. Interv. 3, 466 (2003). 2. Takeda, K. et al. Annu. Rev. Immunol. 21, 335 (2003). 3. Janeway, CA Jr. et al. Annu. Rev. Immunol. 20, 197 (2002). 4. O'Neill, LAJ. et al. Trends in Imm. 24 286 (2003). 5. McGettrick, AF. et al. Mol Imm. 41, 577 (2004). 6. Chang, M.X., et al. Vet. Immunol. Immunopathol. 124(3-4):295-301.